AngioDynamics, Inc. Overview
Pro stress-test →AngioDynamics, Inc. (NASDAQ: ANGO), is a medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options. In Q1 FY2026, the company reported net sales of $75.7 million, up 12.2% year-over-year, with exceptional growth in its high-margin Med Tech platforms.
Strategic Profile
Pro stress-test →AngioDynamics has completed a strategic transformation, divesting non-core assets and focusing on high-growth MedTech platforms, driving accelerating revenue and margin improvement. The Med Tech segment showed exceptional performance with 26.1% growth, marking its fourth consecutive quarter of over 20% growth. The company maintains a debt-free balance sheet and is transitioning toward profitability with improving gross margins and positive cash flow expectations.
Competitive Landscape
Pro stress-test →AngioDynamics competes in peripheral vascular disease and oncology markets with differentiated products including the Auryon Atherectomy system for lesion removal, thrombus management portfolio (AlphaVac, AngioVac), and NanoKnife IRE ablation system. Key competitors include AtriCure, Merit Medical Systems, and larger diversified medtech players. The company's focus on minimally invasive platforms with strong clinical support positions it favorably in growing interventional markets.
Industry Context
AngioDynamics, Inc. operates in Medical Devices - Minimally Invasive Surgery and Interventional Medicine.
Key facts
Headquarters: Latham, New York · Revenue: $312-314M (FY2026E) · Market cap: $522-545M